En español

Leading Medication Development Researcher Phil Skolnick joins NIDA to lead Drug Discovery Efforts

January 19, 2010

The National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health, today announced that Phil Skolnick, Ph.D., D.Sc. (hon.), a leader in the worlds of corporate and academic drug research, has been appointed Director of NIDA's Division of Pharmacotherapies and Medical Consequences of Drug Abuse (DPMCDA).

Phil Skolnick, Ph.D., D.Sc.Phil Skolnick, Ph.D., D.Sc.

Dr. Skolnick is currently a research professor of psychiatry at New York University Langone Medical Center. He served as Chief Scientific Officer at DOV Pharmaceutical, Inc., from 2001-2009. Under his leadership, DOV discovered and developed novel reuptake inhibitor platforms, including the first triple (norepinephrine, serotonin, and dopamine) reuptake inhibitor tested in humans. These compounds can be targeted to a wide variety of neuropsychiatric disorders ranging from depression and attention deficit hyperactivity disorder, to pain and obesity. At NIDA, he will lead a team that stimulates and conducts all phases of medications development from synthesis and screening of potential drug entities to preparing submissions for New Drug Applications. The DPMCDA funds research and development through peer reviewed grants and contracts, as well as interagency agreements to support the medications development process and clinical trial infrastructure.

"We are delighted to have Dr. Skolnick join our team of scientists looking for solutions to the management of drug addiction," said NIDA Director Nora Volkow. "His many remarkable years of innovation and leadership in both public and private research arenas will strengthen our complex medications development process and enhance our search for pharmacotherapeutic and immunological treatment agents."

Dr. Skolnick's appointment marks a return to the NIH community. He first joined NIH in 1972 as a staff fellow under Dr. John W. Daly in the National Institute of Arthritis, Metabolism and Digestive Diseases (NIAMDD), now the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK.) After a brief stint as a senior investigator at the National Institute on Alcohol Abuse and Alcoholism, he returned to NIAMDD in 1978. In 1983, he became Chief of the Section on Neurobiology, and in 1986, Chief of the Laboratory of Neuroscience. After a celebrated career as an NIH neurobiologist and more than 500 papers published, Dr. Skolnick retired from government service in 1997 when he accepted a position as a Lilly Fellow in Neuroscience at Eli Lilly.

"I am delighted to return to the NIH community, which was a wonderful professional home for 25 years," said Dr. Skolnick. "My new position at NIDA will enable me to take what I have learned in the private sector about medications development and apply it to the challenging field of drug abuse and addiction."

Dr. Skolnick will take the Division helm from Acting Division Director David McCann, Ph.D. "We would like to thank Dr. McCann for his gracious and capable leadership of this important Division in recent months," added Dr. Volkow. "He kept a strong and dynamic vision as our scientific team prepared for the transition to new leadership." Dr. Skolnick's first day at NIDA will be January 19, 2010.

NIDA Press Office

About the National Institute on Drug Abuse (NIDA): The National Institute on Drug Abuse (NIDA) is a component of the National Institutes of Health, U.S. Department of Health and Human Services. NIDA supports most of the world’s research on the health aspects of drug use and addiction. The Institute carries out a large variety of programs to inform policy, improve practice, and advance addiction science. Fact sheets on the health effects of drugs and information on NIDA research and other activities can be found at www.drugabuse.gov, which is now compatible with your smartphone, iPad or tablet. To order publications in English or Spanish, call NIDA’s DrugPubs research dissemination center at 1-877-NIDA-NIH or 240-645-0228 (TDD) or email requests to drugpubs@nida.nih.gov. Online ordering is available at drugpubs.drugabuse.gov. NIDA’s media guide can be found at www.drugabuse.gov/publications/media-guide/dear-journalist, and its easy-to-read website can be found at www.easyread.drugabuse.gov. You can follow NIDA on Twitter and Facebook.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIH. . .Turning Discovery Into Health®

News Releases

Mar 2017

Feb 2017

Dec 2016

Nov 2016

Oct 2016

Sep 2016

Aug 2016

Jul 2016

Jun 2016

May 2016

Apr 2016

Mar 2016

Feb 2016

Jan 2016

Dec 2015

Nov 2015

Oct 2015

Sep 2015

Aug 2015

Jul 2015

Jun 2015

May 2015

Apr 2015

Mar 2015

Feb 2015

Jan 2015

Dec 2014

Nov 2014

Oct 2014

Sep 2014

Aug 2014

Jul 2014

Jun 2014

May 2014

Apr 2014

Mar 2014

Feb 2014

Jan 2014

Dec 2013

Nov 2013

Oct 2013

Sep 2013

Aug 2013

Jul 2013

Jun 2013

May 2013

Apr 2013

Mar 2013

Feb 2013

Jan 2013

Dec 2012

Nov 2012

Oct 2012

Sep 2012

Aug 2012

Jul 2012

Jun 2012

May 2012

Apr 2012

Mar 2012

Feb 2012

Jan 2012

Dec 2011

Nov 2011

Oct 2011

Sep 2011

Aug 2011

Jul 2011

Jun 2011

May 2011

Apr 2011

Mar 2011

Jan 2011

Dec 2010

Nov 2010

Sep 2010

Aug 2010

Jul 2010

May 2010

Apr 2010

Mar 2010

Jan 2010

Get this Publication

Cite this article

APA style citation

NIDA (). Leading Medication Development Researcher Phil Skolnick joins NIDA to lead Drug Discovery Efforts. Retrieved , from https://www.drugabuse.gov/news-events/news-releases/2010/01/leading-medication-development-researcher-phil-skolnick-joins-nida-to-lead-drug-discovery-e

press ctrl+c to copy
Receive Latest Science Articles in your Email!
You will only receive messages related to Latest Science